Plasma cell leukemia (PCL)
Clinical trials for Plasma cell leukemia (PCL) explained in plain language.
Never miss a new study
Get alerted when new Plasma cell leukemia (PCL) trials appear
Sign up with your email to follow new studies for Plasma cell leukemia (PCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare leukemia: Four-Drug cocktail targets cancer cells
Disease control Recruiting nowThis phase 2 trial tests a new drug combination for adults newly diagnosed with primary plasma cell leukemia, a rare and aggressive blood cancer. The treatment includes CM336 (a bispecific antibody) plus three other drugs. The study aims to see how many patients achieve deep remi…
Matched conditions: PLASMA CELL LEUKEMIA (PCL)
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Personalized immunotherapy strategies aim to improve outcomes for frail myeloma patients
Disease control Recruiting nowThis phase 3 trial is for people newly diagnosed with multiple myeloma who are not healthy enough for a stem cell transplant. After six months of standard treatment with daratumumab, lenalidomide, and dexamethasone, participants are assigned to different immunotherapy combination…
Matched conditions: PLASMA CELL LEUKEMIA (PCL)
Phase 3 • Sponsor: University of Leeds • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Supercharged immune cells take on Hard-to-Treat blood cancer
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy, boosted with IL-15, in 25 people with multiple myeloma or plasma cell leukemia that has come back or not responded to treatment. The therapy uses the patient's own immune cells, engineered to target cancer cells. The goal is to s…
Matched conditions: PLASMA CELL LEUKEMIA (PCL)
Phase 2 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC